Thyroid disorder — all decisions

The Board remands the Veteran's claims for service connection for high cholesterol, hypertension, insomnia, thyroid disease, GERD, and gout due to an error by the agency of original jurisdiction in failing to provide notice of the Veteran's right to a pre-decisional hearing.

The Board granted the request to readjudicate the claim of entitlement to service connection for thyroid enlargement with benign neoplasm, status post right thyroidectomy, due to new and relevant evidence being submitted.

The Board denied service connection for depression, pelvic pain, uterine fibroids, and Tietze syndrome. The initial compensable rating claims for iron deficiency anemia and thyroid enlargement were also denied.

The Board denied service connection for a thyroid disability and a respiratory disorder, to include COPD and emphysema, as the evidence did not support a finding that these conditions were related to the Veteran's military service.

The Board denied service connection for heart disability, hypertension, hypothyroidism, pre-diabetes, and neuropathy of the lower extremities as there was no evidence to support a link between these conditions and the Veteran's military service.

The Board denied the Veteran's claims for increased ratings and remanded several service connection claims.

The Board granted service connection for chronic kidney disease as secondary to the Veteran's service-connected leukemia and remanded several other claims for further development.

The Board granted ratings for hypothyroidism, PTSD, right total hip replacement, and migraine headaches, while denying higher ratings or additional compensation for other conditions.

The Board remands the claim for a higher initial rating for hypothyroidism due to an inadequate VA examination and pre-decisional duty to assist error.

The Board denied service connection for Parkinson's disease and remanded the claims for thyroid cancer and malignant neoplasm of the right and left lung secondary to thyroid cancer due to an inadequate VA examination.

The Board denied service connection for vertigo/dizziness, an eye disability, and a thyroid condition as there was no evidence of in-service incurrence or nexus to service.

The Board remands the claim for a VA medical opinion to discuss potential residuals of post-surgical hypothyroidism and the beneficial effects of medication.

The Veteran's service-connected hypertension was granted a 10 percent disability rating, while the claim for an initial compensable disability rating for hypothyroidism was remanded.

The Board denied the claims for increased ratings for diabetes mellitus, hypertension, and hypothyroidism, as well as remanded the claims for service connection of left and right hip disabilities.

The Board denied service connection for restless leg syndrome and hyperlipidemia, and remanded claims for chronic kidney disease, kidney cyst, coronary artery disease with RCA stent implants, hypertension, diabetes mellitus type II, a skin condition, GERD, hypothyroidism, Raynaud's syndrome, and sleep apnea.

The Board denied the veteran's claims for increased ratings and service connection, as well as an earlier effective date for a grant of service connection.

The Board granted service connection for a cervical spine disorder but denied service connection for psoriasis, varicose veins, nodule on right thyroid, sinusitis, allergic rhinitis, and gynecological disorder.

The Board granted a rating of 30 percent for hypothyroidism and a rating of 70 percent for an acquired psychiatric disorder, to include chronic adjustment disorder (adjustment disorder with mixed anxiety and depressed mood).

The Board denied service connection for hypothyroidism, GERD, and bruxism. The Veteran's PTSD was not granted an earlier effective date prior to December 28, 2020, or a higher rating before April 23, 2021. The back disability claim was also denied.

The Board granted service connection for diabetes mellitus, type II, due to presumed exposure to herbicide agents during the Vietnam War era. The claims for thyroid cancer, melanoma, and sleep apnea were remanded for further development.